EP1601357A4 - HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS - Google Patents

HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS

Info

Publication number
EP1601357A4
EP1601357A4 EP04719237A EP04719237A EP1601357A4 EP 1601357 A4 EP1601357 A4 EP 1601357A4 EP 04719237 A EP04719237 A EP 04719237A EP 04719237 A EP04719237 A EP 04719237A EP 1601357 A4 EP1601357 A4 EP 1601357A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
methods
kinase inhibitors
heterocyclic kinase
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04719237A
Other languages
German (de)
French (fr)
Other versions
EP1601357A1 (en
Inventor
M Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1601357A1 publication Critical patent/EP1601357A1/en
Publication of EP1601357A4 publication Critical patent/EP1601357A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP04719237A 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS Withdrawn EP1601357A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US453457P 2003-03-10
US46091003P 2003-04-07 2003-04-07
US460910P 2003-04-07
US46302503P 2003-04-15 2003-04-15
US463025P 2003-04-15
US50271003P 2003-09-12 2003-09-12
US502710P 2003-09-12
PCT/US2004/007286 WO2004080463A1 (en) 2003-03-10 2004-03-10 Heterocyclic kinase inhibitors: methods of use and synthesis

Publications (2)

Publication Number Publication Date
EP1601357A1 EP1601357A1 (en) 2005-12-07
EP1601357A4 true EP1601357A4 (en) 2007-10-03

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04719237A Withdrawn EP1601357A4 (en) 2003-03-10 2004-03-10 HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS

Country Status (5)

Country Link
EP (1) EP1601357A4 (en)
JP (1) JP2006519846A (en)
CA (1) CA2518398A1 (en)
MX (1) MXPA05009722A (en)
WO (1) WO2004080463A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
KR20080000665A (en) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 Dipeptidyl Peptidase-IV Inhibitors
MX2008002363A (en) * 2005-08-17 2008-03-18 Schering Corp Novel high affinity quinoline-based kinase ligands.
DK3421471T3 (en) 2006-04-25 2021-06-14 Astex Therapeutics Ltd PURIN AND DEAZAPURIN DERIVATIVES AS PHARMACEUTICAL COMPOUNDS
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
WO2008059370A2 (en) 2006-11-17 2008-05-22 Pfizer Japan Inc. Substituted bicyclocarboxyamide compounds
CN101541753B (en) 2006-12-07 2012-06-13 弗·哈夫曼-拉罗切有限公司 2-aminoquinolines as 5-HT(5A) receptor antagonists
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
AU2008260647A1 (en) * 2007-05-23 2008-12-11 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
BRPI0816239A2 (en) * 2007-08-22 2015-02-24 Allergan Inc Quinoline and Naphthalene Therapeutic Derivatives
CA2699697A1 (en) * 2007-09-27 2009-04-02 F. Hoffmann-La Roche Ag Quinoline derivatives as 5ht5a receptor antagonists
PL2201012T3 (en) 2007-10-11 2014-11-28 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
WO2009051112A1 (en) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
BRPI0909634A2 (en) * 2008-03-05 2015-09-22 Hoffmann La Roche 2-aminoquinolines
BRPI0910253A2 (en) 2008-03-07 2015-09-29 Hoffmann La Roche 2-aminoquinoline derivatives
AU2009221294A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinolines
MX2010009820A (en) 2008-03-12 2010-10-15 Hoffmann La Roche 2-aminoquinolines as 5-ht5a receptor antagonists.
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
MY159327A (en) 2009-02-27 2016-12-25 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
AU2010221417A1 (en) * 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
SI2440547T1 (en) * 2009-06-12 2023-05-31 Abivax New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
PT2512243E (en) * 2009-12-17 2016-06-08 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators
PH12012501535A1 (en) 2010-01-29 2012-10-22 Boehringer Ingelheim Int Substituted naphthyridines and their use as syk kinase inhibitors
EP2582676B1 (en) * 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
CA2805932A1 (en) * 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
WO2012030948A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2684167B1 (en) * 2011-03-08 2020-09-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
EA027506B1 (en) 2011-04-01 2017-08-31 Астразенека Аб Method of treating breast cancer
EP2706853B1 (en) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
KR101986484B1 (en) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinolines and their use as medicaments
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
HRP20191982T4 (en) 2011-11-30 2023-01-06 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2863914B1 (en) 2012-06-20 2018-10-03 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (en) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド Methods of determining chemosensitivity and chemotoxicity
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
TR201900148T4 (en) * 2014-10-31 2019-02-21 Genoscience Pharma Sas 2,4 diamino-quinoline substituted as novel agents against cancer.
DK3452465T3 (en) * 2016-05-04 2021-02-08 Genoscience Pharma SUBSTITUTED 2,4-DIAMINOQUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
AU2018286247B2 (en) * 2017-06-14 2021-12-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Syk inhibitor and use method therefor
EP3658560A4 (en) * 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES OF THESE LATEST
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020119785A1 (en) * 2018-12-14 2020-06-18 正大天晴药业集团股份有限公司 Salt of syk inhibitor and crystalline form thereof
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (en) 2020-07-02 2023-08-15 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
WO2023099589A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (en) * 1926-05-04 1933-03-17 Chem Ind Basel Process for the preparation of substituted quinolinecarboxamides
DE858698C (en) * 1951-02-09 1952-12-08 Basf Ag Process for the preparation of pyridine and quinoline derivatives
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
FR6103M (en) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (en) * 1982-12-24 1985-06-21 Pharmuka Lab NOVEL NAPHTHALENE- OR AZANAPHTHALENECARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
JPH05310702A (en) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd Anti-inflammatory agent, immunomodulating agent and quinoline-2,4-dicarboxylic acid diamide derivative
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU3386700A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP3715280B2 (en) * 2001-05-21 2005-11-09 エフ．ホフマン−ラ ロシュ アーゲー Quinoline derivatives as ligands for neuropeptide Y receptors
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (en) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (en) * 1926-05-04 1933-03-17 Chem Ind Basel Process for the preparation of substituted quinolinecarboxamides
DE858698C (en) * 1951-02-09 1952-12-08 Basf Ag Process for the preparation of pyridine and quinoline derivatives
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (en) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited 2-pyrimidineamine derivatives and processes for their preparation
WO2002014269A2 (en) * 2000-08-16 2002-02-21 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2003078404A1 (en) * 2002-03-15 2003-09-25 Novartis Ag Pyrimidine derivatives
WO2004002960A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2004081531A2 (en) * 2003-03-10 2004-09-23 Schering Corporation Ligand analysis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, M.; ET AL., TETRAHEDRON LETTERS, vol. 29, no. 48, 1988, pages 6287 - 6290, XP002445489 *
ILLUMINATI, G.; GILMAN, H., J. AM. CHEM. SOC., vol. 71, 1949, pages 3349 - 3351, XP002445491 *
SARGENT, H., J. AM. CHEM. SOC., vol. 68, 1964, pages 2688 - 2692, XP002445490 *
See also references of WO2004080463A1 *
WEISS, M.J.; HAUSER, C.R., J. AM. CHEM. SOC., vol. 71, 1949, pages 2026 - 2027, XP002445492 *

Also Published As

Publication number Publication date
JP2006519846A (en) 2006-08-31
MXPA05009722A (en) 2006-03-09
WO2004080463A1 (en) 2004-09-23
CA2518398A1 (en) 2004-09-23
EP1601357A1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
EP1601357A4 (en) HETEROCYCLIC KINASE INHIBITORS: METHODS OF USE AND SYNTHESIS
EP1507541A4 (en) INHIBITORS AND METHODS OF USE THEREOF
EP1606285A4 (en) IDO INHIBITORS AND METHODS OF USE THEREOF
EP1691812A4 (en) GTPASE INHIBITORS AND METHODS OF USING SAME
EP1603567A4 (en) TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE
EP1723227A4 (en) NICOTINAMIDE RIBOSIDE KINASE COMPOSITIONS AND METHODS OF USE
EP1831207A4 (en) AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
NO20045220L (en) Heterocyclic Inhibitors of Kinases
EP1644323A4 (en) HISTONE DESACETYLASE INHIBITORS AND METHODS OF USE
EP1181293A4 (en) CUCURBITURILS AND METHODS OF SYNTHESIS
EP1620095A4 (en) INHIBITORS OF AKT ACTIVITY
EP1552002A4 (en) TOXIN-APTAMERE MOLECULES AND METHODS OF USING SAME
EP1583950A4 (en) TEST CARTRIDGES AND METHODS OF USE
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
EP1603568A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE
MA29029B1 (en) THIADIAZOLE COMPOUNDS AND METHODS OF USE
ATE359787T1 (en) CONTROLLED SYNTHESIS OF ZIPRASIDONE
EP1855833A4 (en) PLASMAS AND METHODS OF USE
PL376789A1 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
NL1027811A1 (en) Heterocyclic amines as inhibitors of 11-hydroxy-steroid-dehydrogenase type 1.
EP1706791A4 (en) PHOTORESIN COMPOSITIONS AND METHODS OF USE
EP1694866A4 (en) GENE EXPRESSION PROFILES AND METHODS OF USE
EP1913112A4 (en) SUPPORTING AGENT AND METHODS OF USE
EP1722797A4 (en) ISOQUINOLINE DERIVATIVES AND METHODS OF USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077021

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070830

17Q First examination report despatched

Effective date: 20080603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077021

Country of ref document: HK